Traditionally considered as a critical intermediate in the toxic and carcinogenic response to
dioxin (2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, TCDD), the Aryl hydrocarbon/Dioxin receptor …

Breast cancer is a sporadic disease with genetic and epigenetic components. Genomic
instability in breast cancer leads to mutations, copy number variations, and genetic …

Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast
cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that …

Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient
receives endocrine therapy, but does not guarantee patient response. The molecular factors …

Simple Summary Epigenetic therapies are promising agents for overcoming clinical
resistance to conventional treatments in breast cancer. In the assessed trials, the use of …

Scope Reduced expression of tumor suppressor genes (TSG) increases the susceptibility to
breast cancer. However, only a small percentage of breast tumors is related to family history …

Background: Breast cancer (BrC) is the most frequent neoplasm in women. New biomarkers,
including aberrant DNA methylation, may improve BrC management. Herein, we evaluated …

Over the last years, epigenetic changes, including DNA methylation and histone
modifications detected in early tumorigenesis and cancer progression, have been proposed …

Compelling evidence has demonstrated that tumor bulk comprises distinctive subset of cells
generally referred as cancer stem cells (CSCs) that have been proposed as a strong …

Differentiation of stem cells into highly specialised cells requires gene expression changes
brought about by remodelling of the chromatin architecture. During this lineage-commitment …